Pune, Maharashtra -- (SBWIRE) -- 08/28/2018 -- Global Pulmonary Arterial Hypertension (PAH) Market: Industry Analysis & Outlook (2018-2022)-
The report provides a unique tool for evaluating the market, highlighting opportunities, and supporting strategic and tactical decision-making. This report recognizes that in this rapidly-evolving and competitive environment, up-to-date marketing information is essential to monitor performance and make critical decisions for growth and profitability. The research study focuses major leading industry players with information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. It provides information on trends and developments, and focuses on markets and materials, capacities and technologies, and on the changing structure of the Pulmonary Arterial Hypertension (PAH) Market.
Request a Sample copy of this report at: https://www.industrydataanalytics.com/request-sample-page.php?gturl=global-pulmonary-arterial-hypertension-pah-market-industry-analysis-outlook-2018-2022-koncpt00180
Pulmonary arterial hypertension (PAH) is one form of pulmonary hypertension (PH) condition, which means high blood pressure in the lungs. Many diseases such as obstructive sleep apnea (OSA), lung diseases, diastolic heart failure and diseases of the left heart can cause the pressures in the pulmonary arteries to elevate but is not pulmonary arterial hypertension. PAH is a life threatening disease characterized by an increase in pulmonary vascular resistance that eventually leads to death. It is a rare disease, affects about 15-70 people per million in the U.S. The symptoms of PAH are difficult to diagnose as the symptoms are common to other diseases.
Pulmonary arterial hypertension is a severe condition and there is no cure to PAH at present time. Many treatments are available to improve symptoms, quality of life and to keep the condition under control. There are currently four classes of drugs approved for the treatment of PAH and 13 approved products are available for PAH in the market across these four drug classes.
MARKET DYNAMICS
Growth Drivers-:
1. Increasing Healthcare Spending
2. Rising Ageing Population
3. Accelerating Economic Growth
4. Growing Female Population
5. Increase in Obese Population
6. Unmet Medical Needs
Key Trends and Developments-:
1. Growing Number of Cardiac Diseases
2. Growing Consumption of Fast Food
3. Favorable Government Support
Challenges-:
1. High Costs of Diagnosis and Treatment
2. Lack of Awareness
3. Expiry of Patents
The United States is the main contributor to the PAH market with the development of new therapies and increasing cases of pulmonary arterial hypertension. The U.S. has great potential in the years ahead with rising awareness about treatment options of PAH.
The global PAH market is expected to grow in the future due to increasing ageing population, rise in healthcare expenditure, growing women population, increase in obese population and high unmet needs. Key trends of this market include increasing number of cardiovascular diseases, rising government support, and consumption of junk food. However, there are some factors which can hinder the growth of the market which includes patent expiration, high cost and lack of awareness.
The report ÒGlobal Pulmonary Arterial Hypertension Market: Industry Analysis & Outlook (2018-2022)Ó by Koncept Analytics provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering The United States and Europe region along with the global market. The report profiles the key players in the market including Johnson & Johnson, Gilead Sciences, United Therapeutics and GlaxoSmithKline.
Browse Full Report at: https://www.industrydataanalytics.com/global-pulmonary-arterial-hypertension-pah-market-industry-analysis-outlook-2018-2022-koncpt00180-p.php
Key Benefits for Stakeholders:
- The Pulmonary Arterial Hypertension (PAH) Market report provides in-depth market analysis of the global Pulmonary Arterial Hypertension (PAH) market, highlighting the current trends, key driving factors, and potential areas for investments.
- The leading industry players are analyzed in terms of their product portfolio, M&A, and future potential development strategies.
- Strategic recommendations in key business sections in light of the market estimations are included in the study.
- Company profiling with comprehensive approaches and methodologies, financial, and latest technological developments.
This report on Global Pulmonary Arterial Hypertension (PAH) Market is a detailed research study that helps provides answers and pertinent questions with respect to the emerging trends and growth opportunities in this industry. It helps identify each of the prominent barriers to growth, apart from identifying the trends within various application segments of the global market for Pulmonary Arterial Hypertension (PAH). Collecting historical and recent data from various authentic resources and depending on all the factors and trends, the report presents a figurative estimate of the future market condition, along with compound annual growth rate (CAGR).
About Industrydataanalytics
Industrydataanalytics provides syndicated Market research reports to industries, organizations or even individuals with an aim of helping them in their decision making process. Industrydataanalytics has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
+1 (704) 266-3234 | mail to: sales@industrydataanalytics.com